Related Experiment Videos
Sustained release verapamil in renal hypertension
H Eiskjaer1, E B Pedersen, L M Rasmussen
1Department of Medicine C, Aarhus Kommunehospital and Aarhus University, Denmark.
European Journal of Clinical Pharmacology
|January 1, 1988
Summary
Sustained release verapamil moderately lowered blood pressure in patients with chronic kidney disease. This hypertension treatment did not affect kidney function, hormones, or body weight.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Arterial hypertension is a common complication in patients with chronic renal parenchymal disease.
- Impaired renal function can exacerbate hypertension and complicate treatment.
- Understanding the effects of antihypertensive medications in this population is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of sustained release verapamil in patients with hypertension secondary to chronic renal disease.
- To assess the impact of verapamil on blood pressure, renal function, hormonal levels, and lipid profiles.
Main Methods:
- A randomized, placebo-controlled study involving 14 patients with hypertension and chronic renal disease.
- Patients received placebo and sustained release verapamil (240 mg/day) for consecutive 3-week periods.
- Measurements included 24-h ambulatory and casual blood pressure, plasma hormones, creatinine clearance, lipids, and body weight.
Main Results:
- Sustained release verapamil significantly reduced mean 24-h ambulatory blood pressure (152/104 to 142/97 mm Hg) and casual blood pressure (176/106 to 154/96 mm Hg).
- Blood pressure reduction was observed during daytime and evening, but not at night.
- No significant changes were noted in hormones, creatinine clearance, plasma lipids, heart rate, or body weight.
Conclusions:
- Sustained release verapamil (240 mg/day) provides a moderate hypotensive effect in patients with chronic renal disease.
- The treatment was well-tolerated, without adverse effects on renal function, hormonal balance, or metabolic parameters.
- A negative correlation between atrial natriuretic peptide and creatinine clearance suggests extracellular volume expansion in advanced renal disease.